Leukemia research reports · 2026
The prognostic value of KRAS, NRAS, and BRAF genes mutations in patients with newly diagnosed multiple myeloma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pham Phuong Thao, Nguyen Hoang Viet, Vu Minh Phuong
Аннотация
BACKGROUND: KRAS, NRAS, and BRAF (RAS/RAF) genes mutations play a role in the pathogenesis of multiple myeloma (MM). We conducted this study to investigate whether RAS/RAF genes mutations have a prognostic value in patients with MM.
MATERIAL AND METHODS: 117 newly diagnosed MM patients underwent the FISH technique to detect high-risk cytogenetic abnormalities and next-generation sequencing (NGS) to detect KRAS, NRAS, BRAF and TP53 mutations.
RESULTS: In the study patient group, patients with the KRAS mutation had significantly longer OS and PFS compared to those with the TP53 mutation; patients with the BRAF mutation had significantly longer OS compared to those with the TP53 mutation. In the patient without high-risk cytogenetics based on FISH, patients with the KRAS mutation had significantly longer OS and PFS compared to those with the TP53 mutation. Conversely, in the patients with high-risk cytogenetics based on FISH, no difference in survival time has been observed among patient groups harboring different gene mutations.
CONCLUSIONS: RAS/RAF gene mutations may have important prognostic implications for MM but should be considered in conjunction with other abnormalities, such as chromosomal abnormalities and TP53 mutations.
MATERIAL AND METHODS: 117 newly diagnosed MM patients underwent the FISH technique to detect high-risk cytogenetic abnormalities and next-generation sequencing (NGS) to detect KRAS, NRAS, BRAF and TP53 mutations.
RESULTS: In the study patient group, patients with the KRAS mutation had significantly longer OS and PFS compared to those with the TP53 mutation; patients with the BRAF mutation had significantly longer OS compared to those with the TP53 mutation. In the patient without high-risk cytogenetics based on FISH, patients with the KRAS mutation had significantly longer OS and PFS compared to those with the TP53 mutation. Conversely, in the patients with high-risk cytogenetics based on FISH, no difference in survival time has been observed among patient groups harboring different gene mutations.
CONCLUSIONS: RAS/RAF gene mutations may have important prognostic implications for MM but should be considered in conjunction with other abnormalities, such as chromosomal abnormalities and TP53 mutations.